The American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) has extended the draft recommendations and guideline feedback for professional and public comment until June 19, 2017 on:
- Draft Recommendations from the 2017 ASCO/CAP Focused Update Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 (HER2) Testing in Breast Cancer.
- General input for possible revision to the 2010 ASCO/CAP Guideline Recommendations for Immunohistochemical (IHC) Testing of Estrogen and Progesterone Receptors (ER/PgR) in Breast Cancer.
The information, data, and draft recommendations that ASCO and the CAP provide here are presented for informational and public feedback purposes only. The draft recommendations and supporting documents will be removed from public domain on June 19, 2017. All comments received will be made available for public viewing until June 26, 2017. These draft materials should not be stored, adapted, or redistributed in any manner.
All stakeholders including oncologists, pathologists, surgeons, nurses, allied health professionals, hospital or laboratory administrators, public health and industry professionals, patient advocacy group representatives, and patients are urged to review and provide commentary. All health systems with all levels of IHC and in situ hybridization (ISH) experience including US and international based laboratories are encouraged to submit comments.